雷替曲塞联合奈达铂同步调强放疗治疗局部晚期食管癌的临床疗效

目的探讨雷替曲塞联合奈达铂同步调强放疗治疗局部晚期食管癌的临床疗效。方法将局部晚期食管癌80例根据治疗方法分为采用雷替曲塞联合奈达铂同步调强放疗组(观察组)38例,采用顺铂联合5-FU同步调强放疗治疗组(对照组)42例,比较2组患者实体瘤的疗效指标,比较2组的不良反应。结果观察组CR为57.9%、PR为39.5%、DCR为97.4%,而对照组CR为47.6%、PR为45.2%、DCR为92.9%。观察组的DCR与对照组相比,差异无统计学意义(χ^2=0.731,P=0.621)。2组患者各项不良反应对比差异均无统计学意义(P>0.05)。结论雷替曲塞联合奈达铂同步调强放疗治疗局部晚期食管癌是有效的及安全的临床治疗方案,其临床应用方便,耐受性良好。

Clinical Efficacy of Raltitrex Combined with Nedaplatin in the Treatment of Locally Advanced Esophageal Cancer

Objective To investigate the clinical efficacy of raltitrexed combined with nedaplatin in the treatment of locally advanced esophageal cancer.Methods 80 patients with locally advanced esophageal carcinoma were divided into 3 groups according to the treatment method:leititrexed plus nedaplatin synchronous intensity-modulated radiotherapy group(observation group),cisplatin combined with 5-FU synchronous intensity-modulated radiotherapy group(control Group)of 42 patients,comparing the efficacy of solid tumors in the 2 groups of patients,comparing the adverse reactions of the 2 groups.Results The CR of the observation group was 57.9%,the PR was 39.5%,and the DCR was 97.4%.The CR of the control group was 47.6%,the PR was 45.2%,and the DCR was 92.9%.There was no difference in the DCR between the 2 groups.Academic significance(χ~2=0.731,P=0.621).There was no significant difference in the adverse reactions between the 2 groups(P>0.05).Conclusion Rertixe combined with nedaplatin combined with intensity-modulated radiotherapy is an effective and safe clinical treatment for locally advanced esophageal cancer.It has convenient clinical application and good tolerance.